Statins are associated with reduced likelihood of sarcopenia in a sample of heart failure outpatients: a cross-sectional study
Authors:
Open Access
- 5 August 2022
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 22 (1) , 1-11
Abstract
Background: Sarcopenia is prevalent in heart failure (HF) patients, contributing to its poor prognosis. Statin use is postulated as a probable risk for developing sarcopenia, but little is known regarding this association in HF patients. This work aims at classifying and characterising sarcopenia and at describing the association of statin use with sarcopenia in a sample of Portuguese HF outpatients. Methods: In this cross-sectional study, a sample of 136 HF patients (median age: 59 years, 33.8% women) was recruited from an HF outpatients’ clinic of a University Hospital in Portugal. Sarcopenia was defined according to the European Working Group on Sarcopenia in Older People 2. Clinical, nutritional, and dietary data were collected. Results: A total of 25 (18.4%) individuals were categorised as sarcopenic, ranging from 12.2% in younger (< 65 years) participants vs. 30.4% in older ones and from 3.3% in men vs. 47.8% in women. Severe sarcopenia accounted for 7.4% of the sample and sarcopenic obesity was identified in 5.1% of the individuals. A total of 65.4% of the participants were statin users. In multivariable analysis (n = 132, 25 sarcopenic), the use of statins was inversely associated with sarcopenia (OR = 0.03; 95% CI = 0.01, 0.30). Each additional age year was associated with a 9% increase in the likelihood of being sarcopenic (OR = 1.09; 95% CI = 1.01, 1.17), and each Kg.m−2 increment in body mass index was associated with a 21% decrease in the likelihood of sarcopenia (OR = 0.79; 95% CI = 0.65, 0.96). The daily use of five or more medicines was also directly associated with sarcopenia (OR = 26.87; 95% CI = 2.01, 359.26). On the other hand, being a man and being physically active were inversely associated with sarcopenia (OR = 0.01; 95% CI = 0.00, 0.07 and OR = 0.09; 95% CI = 0.01, 0.65, respectively). Conclusions: Contrary to what was expected, patients medicated with statins were less likely to be sarcopenic. Although this finding deserves further research, we hypothesise that this might be related to the pleiotropic effects of statins on endothelial function, contributing to better neuromuscular fitness.Keywords
This publication has 48 references indexed in Scilit:
- Calf circumference, frailty and physical performance among older adults living in the communityClinical Nutrition, 2014
- Triceps Skinfold as a Prognostic Predictor in Outpatient Heart FailureArquivos Brasileiros de Cardiologia, 2013
- Sarcopenia as a risk factor for falls in elderly individuals: Results from the ilSIRENTE studyClinical Nutrition, 2012
- The obesity paradox in elderly patients with heart failure: Analysis of nutritional statusNutrition, 2012
- A Systematic Assessment of Causes of Death After Heart Failure Onset in the CommunityCirculation: Heart Failure, 2011
- Number of 24-Hour Diet Recalls Needed to Estimate Energy IntakeAnnals of Epidemiology, 2009
- Sarcopenic obesity: definition, cause and consequencesCurrent Opinion in Clinical Nutrition and Metabolic Care, 2008
- Trends in Heart Failure Incidence and Survival in a Community-Based PopulationJAMA, 2004
- International Physical Activity Questionnaire: 12-Country Reliability and ValidityMedicine & Science in Sports & Exercise, 2003
- Pharmacologic characteristics of statinsClinical Cardiology, 2003